Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women-Reference-Cited by-同舟云学术

Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women

Published:2004-07 Issue:21-22 Volume:22 Page:2943-2952
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Fife Kenneth H,Wheeler Cosette M,Koutsky Laura A,Barr Eliav,Brown Darron R,Schiff Melissa A,Kiviat Nancy B,Jansen Kathrin U,Barber Harriet,Smith Judith F,Tadesse Amha,Giacoletti Katherine,Smith Paula R,Suhr Gretchen,Johnson Daniel A

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference42 articles.

1. Epidemiology of genital human papillomavirus infection;Koutsky;Am. J. Med.,1997

2. American Social Health Association Panel: estimates of the incidence and prevalence of sexually transmitted diseases in the United States;Cates;Sex Transm. Dis.,1999

3. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia;Schiffman;J. Natl. Cancer Inst.,1993

4. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective;Bosch;J. Natl. Cancer Inst.,1995

5. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide;Walboomers;J. Pathol.,1999

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human Papillomavirus Vaccines;Plotkin's Vaccines;2023

2. Immune Responses to Human Papillomavirus and the Development of Human Papillomavirus Vaccines;Human Papillomavirus;2020

3. Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature;Papillomavirus Research;2019-12

4. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial;The Lancet Infectious Diseases;2019-10

5. Human Papillomavirus Vaccines;Plotkin's Vaccines;2018